Frequency of fibroblast growth factor receptor 3 mutations in sporadic tumours.

2.50
Hdl Handle:
http://hdl.handle.net/10541/85761
Title:
Frequency of fibroblast growth factor receptor 3 mutations in sporadic tumours.
Authors:
Sibley, Kathryn; Stern, Peter L; Knowles, Margaret A
Abstract:
Mutations in FGFR3 have been identified in several tumour types including bladder carcinoma, cervical carcinoma, and multiple myeloma. In bladder carcinoma, we recently identified FGFR3 mutations in 41% of tumours, making this the most frequently mutated putative oncogene identified in bladder cancer to date. We have now investigated the frequency of FGFR3 mutation in a panel of 125 tumours and 13 cell lines from various other organs. We analysed the mutation hotspots in exons 7, 10 and 15 by direct DNA sequencing, and found one mutation in exon 7 (S249C) in 1/28 (3.5%) cervical tumours. Mutations were not detected in stomach, rectum, colon, prostate, ovarian, breast, brain, or renal tumours, nor were they found in any of the cell lines included in this study. We conclude that FGFR3 is commonly mutated in bladder carcinoma and only rarely in cervical carcinoma. Several tumour types appear not to possess any mutations in FGFR3, suggesting that these mutations are important only in the development of certain types of tumour.
Affiliation:
ICRF Clinical Centre, St. James's University Hospital, Leeds, LS9 7TF, UK.
Citation:
Frequency of fibroblast growth factor receptor 3 mutations in sporadic tumours. 2001, 20 (32):4416-8 Oncogene
Journal:
Oncogene
Issue Date:
19-Jul-2001
URI:
http://hdl.handle.net/10541/85761
PubMed ID:
11466624
Type:
Article
Language:
en
ISSN:
0950-9232
Appears in Collections:
All Paterson Institute for Cancer Research

Full metadata record

DC FieldValue Language
dc.contributor.authorSibley, Kathrynen
dc.contributor.authorStern, Peter Len
dc.contributor.authorKnowles, Margaret Aen
dc.date.accessioned2009-11-10T10:31:38Z-
dc.date.available2009-11-10T10:31:38Z-
dc.date.issued2001-07-19-
dc.identifier.citationFrequency of fibroblast growth factor receptor 3 mutations in sporadic tumours. 2001, 20 (32):4416-8 Oncogeneen
dc.identifier.issn0950-9232-
dc.identifier.pmid11466624-
dc.identifier.urihttp://hdl.handle.net/10541/85761-
dc.description.abstractMutations in FGFR3 have been identified in several tumour types including bladder carcinoma, cervical carcinoma, and multiple myeloma. In bladder carcinoma, we recently identified FGFR3 mutations in 41% of tumours, making this the most frequently mutated putative oncogene identified in bladder cancer to date. We have now investigated the frequency of FGFR3 mutation in a panel of 125 tumours and 13 cell lines from various other organs. We analysed the mutation hotspots in exons 7, 10 and 15 by direct DNA sequencing, and found one mutation in exon 7 (S249C) in 1/28 (3.5%) cervical tumours. Mutations were not detected in stomach, rectum, colon, prostate, ovarian, breast, brain, or renal tumours, nor were they found in any of the cell lines included in this study. We conclude that FGFR3 is commonly mutated in bladder carcinoma and only rarely in cervical carcinoma. Several tumour types appear not to possess any mutations in FGFR3, suggesting that these mutations are important only in the development of certain types of tumour.en
dc.language.isoenen
dc.subjectCancer DNAen
dc.subjectCanceren
dc.subjectCultured Tumour Cellsen
dc.subjectUrinary Bladder Canceren
dc.subjectUterine Cervical Canceren
dc.subject.meshCarcinoma-
dc.subject.meshDNA, Neoplasm-
dc.subject.meshFemale-
dc.subject.meshHumans-
dc.subject.meshMutation-
dc.subject.meshNeoplasms-
dc.subject.meshProtein-Tyrosine Kinases-
dc.subject.meshReceptor, Fibroblast Growth Factor, Type 3-
dc.subject.meshReceptors, Fibroblast Growth Factor-
dc.subject.meshTumor Cells, Cultured-
dc.subject.meshUrinary Bladder Neoplasms-
dc.subject.meshUterine Cervical Neoplasms-
dc.titleFrequency of fibroblast growth factor receptor 3 mutations in sporadic tumours.en
dc.typeArticleen
dc.contributor.departmentICRF Clinical Centre, St. James's University Hospital, Leeds, LS9 7TF, UK.en
dc.identifier.journalOncogeneen

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.